Liang P. Koh

Singapore, Singapore

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Overcoming Donor-Specific Anti-Human Leukocyte Antigen Antibodies With Desensitization in Adult Ex-Vivo T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation: A Real-World Analysis.

Overcoming Donor-Specific Anti-Human Leukocyte Antigen Antibodies With Desensitization in Adult Ex-Vivo T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation: A Real-World Analysis.

Journal: Transplantation and cellular therapy

Published: January 28, 2026

Reducing inappropriate antibiotic use in febrile neutropenia in hematology patients through the implementation of an antibiotic de-escalation protocol.

Reducing inappropriate antibiotic use in febrile neutropenia in hematology patients through the implementation of an antibiotic de-escalation protocol.

Journal: Infection control and hospital epidemiology

Published: May 16, 2025

Impact of C-MYC/BCL2 Double Expression on Survival Outcomes After Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma-A Nationwide Retrospective Analysis in Singapore.

Impact of C-MYC/BCL2 Double Expression on Survival Outcomes After Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma-A Nationwide Retrospective Analysis in Singapore.

Journal: Hematological oncology

Published: August 02, 2024

EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML.

EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML.

Journal: Leukemia

Published: March 13, 2024

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.

Journal: Transplantation and cellular therapy

Published: January 04, 2023

An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma.

An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma.

Journal: Science translational medicine

Published: October 19, 2022

Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood.

Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood.

Journal: Transplantation and cellular therapy

Published: August 11, 2022

Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis.

Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis.

Journal: Blood

Published: February 08, 2022

Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma.

Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: August 13, 2021

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.

Journal: Cancer immunology, immunotherapy : CII

Published: June 12, 2021

Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.

Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.

Journal: British journal of haematology

Published: May 16, 2021

Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective.

Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective.

Journal: Journal of medical economics

Published: April 27, 2021

Showing 1-12 of 35

Last Updated: 09/26/2026